Perrigo launches 2 generics
Perrigo has introduced two products, a generic of Mycolog II Cream (nystatin and triamcinolone acetonide cream, 1 mg/gram) and the Exalgo (hydromorphone HCl) extended-release tablets.
The Dublin, Ireland-based company’s Mycolog II Cream generic is indicated to treat cutaneous candidiasis. The drug had annual generics sales of $81 million for the 12 months ended September 2017, according to IQVIA data.
Perrigo’s Exalgo generic will be available in 32-mg dosage strength, and is indicated to treat severe pain in opioid-tolerant patients who require around-the-clock pain relief over an extended period of time. The drug had brand and generic U.S. sales of $32 million for the 12 months ended September 2017, according to IQVIA data.
"This launch is another example of the team's hard work in advancing our new product pipeline,” Perrigo executive vice president and president Rx pharmaceuticals John Wesolowski said. “This commitment is driving value for patients by delivering generic products in important treatment categories at more affordable prices.”